Aptabio Therapeutics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Aptabio Therapeutics is listed on KOSDAQ and classified under Health Care, Biotechnology. Its market value is US$143.1M. In FY2025 it reported revenue of US$2.8M and an operating loss of US$12M.
A written company profile is not available yet; the facts above come from exchange and DART data.
Aptabio Therapeutics in five facts
Where is Aptabio Therapeutics listed and in which sector?
Aptabio Therapeutics (Korean name: 압타바이오) trades under KRX code 293780 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is Aptabio Therapeutics?
Its market capitalisation was US$143.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Aptabio Therapeutics's latest annual revenue and operating profit?
For fiscal year 2025, Aptabio Therapeutics reported revenue of US$2.8M, an operating loss of US$12M and a net loss of US$12.3M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 10.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 14
- Investor relations (IR) meetingSep 2
- Early redemption of convertible bonds (incl. overseas CBs)
Aptabio Therapeutics Co., Ltd. redeemed US$3.22M face amount of its Series 1 convertible bonds (issued 2023-08-24, maturing 2028-08-24, conversion price US$5.24/share) before maturity at the bondholder's put-option request, paying US$3.52M including interest on 2026-08-24 from its own funds; US$2.03M of the series remains outstanding and the acquired bonds will be retired.
Capital raise · Aug 24 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Aptabio Therapeutics reported consolidated results for FY2025: revenue of US$2.53M (+10% year on year), an operating loss of US$10.9M and a net loss of US$10.7M.
Earnings · Feb 9